Zentalis Pharmaceuticals, Inc. ZNTL
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Zentalis Pharmaceuticals, Inc. (ZNTL) is a healthcare company listed in the US with a market value of about $167M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -50%.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 36% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $67M | $0 | $0 | — | — | — |
| Net income | -$137M | -$166M | -$292M | -$237M | -$159M | -$118M | -$46M |
| Free cash flow | -$125M | -$171M | -$208M | -$166M | -$160M | -$88M | -$39M |
| EPS (diluted) | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 | $-4.19 | $-8.16 |
| Net margin | — | -246.0% | — | — | — | — | — |
| ROIC | -47.2% | -39.8% | -61.9% | -47.1% | -52.7% | -28.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Zentalis Pharmaceuticals pay a dividend?
Not currently.
Is Zentalis Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Zentalis Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.